The Technical Analyst
Zogenix Inc [ZGNX]
Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology
Zogenix Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.00% $26.68
Last updated: 16 May 2022 @ 10:49 am
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 500.17 mill |
| EPS: | -4.07 |
| P/E: | 0.000 |
| Earnings Date: | May 04, 2022 |
| SharesOutstanding: | 56.23 mill |
| Avg Daily Volume: | 3.10 mill |
| RATING 2022-03-18 |
|---|
| B |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/20 | 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | |
| Revenue | ||||||
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$28.56 (7.06%) $1.885 |
| Date: 2022-05-16 |
| True Range Average |
|---|
|
+/- $0.357 ( +/- 1.34%) Range: 26.32 - 27.04 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-03-07 | Smith Michael P | Sell | 35 499 | Restricted Stock Units |
| 2022-03-07 | Smith Michael P | Sell | 35 499 | Restricted Stock Units |
| 2022-03-07 | Smith Michael P | Sell | 8 016 | Common Stock |
| 2022-03-07 | Wiggins Mark C | Sell | 22 000 | Stock Option (Right to Buy) |
| 2022-03-07 | Wiggins Mark C | Sell | 2 500 | Common Stock |
| INSIDER POWER |
|---|
| -47.16 |
| Last 100 transactions |
| Buy: 691 583 | Sell: 1 213 074 |
Forecast:
12:29 - $26.68
Live Trading Signals (every 1 min)
Forecast
1: 10:59 - $26.68
Forecast 2: 11:49 - $26.68
Forecast 3: 12:29 - $26.68
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $26.68 (0.00% ) |
| Volume | 11.25 mill |
| Avg. Vol. | 3.10 mill |
| % of Avg. Vol | 363.20 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ZGNX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since 31-12-69
| Date | Signal | @ | Closed | % | Apr 20 - 15:00 | buy | $26.68 | N/A | Active |
|---|
ZGNX
Latest Press Releases
2022-03-07 12:00:00 - Press Release
Ucb Completes Acquisition Of Zogenix, Inc.
Brussels, belgium and atlanta, march 7, 2022 /prnewswire/ -- ucb (euronext: ucb) today announced the successful completion of the previously announced transaction to acquire zogenix (nasdaq: zgnx) for us$ 26.00 per share plus a milestone-based contingent value right for a potential cash payment of us$ 2.00 per share. the total transaction is valued at up to approximately us $1.9 billion / €1.7 billion*.
2022-03-01 11:35:00 - Press Release
Immunicom Appoints Jennifer Haldeman As Vice President Of Commercial Operations
San diego--(business wire)-- #biotech--immunicom adds jennifer "j.d." haldeman to its senior leadership team. seasoned pharma executive becomes vp of commercial operations for the company.
2022-02-28 08:00:00 - Press Release
Zogenix Provides Corporate Update And Reports Fourth Quarter And Full-year 2021 Financial Results
Emeryville, calif., feb. 28, 2022 (globe newswire) -- zogenix (nasdaq: zgnx), a global biopharmaceutical company developing and rare disease therapies, today provided a corporate update and announced financial results for the fourth quarter and full-year ended december 31, 2021.
2022-02-15 08:00:00 - Press Release
Zogenix Supports New No-cost Genetic Testing Program With United Mitochondrial Disease Foundation To Improve Diagnosis Of Mitochondrial Diseases
Emeryville, calif., feb. 15, 2022 (globe newswire) -- zogenix (nasdaq: zgnx), a global biopharmaceutical company developing rare disease therapies, today announced that the company is sponsoring a new no-cost genetic testing program, the united mitochondrial disease foundation (umdf) pilot genetic testing project, in partnership with umdf and probably genetic, to help patients obtain a confirmed genetic diagnosis of mitochondrial disease. the program is available to any eligible patient in the u.s. with a suspected diagnosis of mitochondrial disease. mitochondrial diseases are a group of rare, debilitating conditions that can severely impact daily living and quality of life, and are often fatal...
2022-01-20 01:20:00 - Press Release
Zogenix Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Zogenix, Inc. - Zgnx
New orleans, jan. 20, 2022 /prnewswire/ -- former attorney general of louisiana charles c. foti, jr., esq.
Latest News
2022-03-04 08:00:00 - GlobeNewsWire
Zogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022
EMERYVILLE, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, announced that new data from the company's research and development program for FINTEPLA® (fenfluramine) in Lennox Gastaut syndrome (LGS) will be presented at the hybrid American Academy of Neurology (AAN) Annual Meeting 2022, in-person in Seattle (April 2-7) and held virtually (April 24-26).
2022-02-28 10:45:26 - Zacks Investment Research
Zogenix (ZGNX) Reports Q4 Loss, Tops Revenue Estimates
Zogenix (ZGNX) delivered earnings and revenue surprises of -8.89% and 1.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
2022-01-21 08:33:43 - The Motley Fool
Why Zogenix Flew Higher Before Leveling Off This Week
2022-01-20 22:07:39 - Stockmarketcom
Top Biotech Stocks To Buy Now? 5 For Your Late January Watchlist
2022-01-20 13:04:19 - Zacks Investment Research
Zogenix (ZGNX) Stock Surges on Acquisition Offer From UCB
Belgium-based UCB is set to acquire Zogenix (ZGNX) for a total transaction value of $1.9 billion in cash. The transaction is likely to be completed by second-quarter 2022.
2022-01-20 09:59:25 - Zacks Investment Research
Zogenix (ZGNX) Stock Jumps 65.7%: Will It Continue to Soar?
Zogenix (ZGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
2022-01-19 11:44:41 - InvestorPlace
ZGNX Stock: The $1.9B UCB Deal That Has Zogenix Shares Zooming Higher Today
Zogenix (ZGNX) stock is skyrocketing on Wednesday following news that UCB (UCBJY) intends to acquire the company in a $1.9 billion deal. The post ZGNX Stock: The $1.9B UCB Deal That Has Zogenix Shares Zooming Higher Today appeared first on InvestorPlace.
2022-01-19 10:18:32 - The Motley Fool
Why Zogenix Stock Is on Fire Today
2022-01-19 09:38:43 - Benzinga
Why Zogenix Shares Are Soaring Today
Zogenix Inc (NASDAQ: ZGNX) is trading significantly higher Wednesday morning after the company announced it received a proposal to be acquired by UCB for approximately $1.9 billion. Under terms of the agreement, UCB will offer to purchase all outstanding shares of Zogenix for $26 per share in cash at closing.
2022-01-19 07:34:51 - Pulse2
Zogenix Stock (ZGNX): Why The Price Went Up Substantially Today
The stock price of Zogenix, Inc. (NASDAQ: ZGNX) increased by over 60% pre-market today. This is why it happened.